Drug Discovery June 15, 2023 Fresenius Kabi introduces Vasopressin Injection, USP, in US By PBR Staff Writer Vasopressin Injection is a generic equivalent to Par Pharmaceutical’s Vasostrict and is available in a single dose vial of 20 units per 1 mL. Fresenius has invested nearly
RegulationApprovals June 14, 2023 Eupraxia’s EP-104IAR secures US FDA Fast Track status By PBR Staff Writer EP-104IAR has been designed for meeting the market demand for long-lasting disease relief in many indications and gain benefit from highly localised and longer delivery of corticosteroids. It
Drug DiscoveryResearch & Development June 13, 2023 Charles River Laboratories, Curigin partner on gene therapy By PBR Staff Writer The partnership will focus on the production of adenoviral vector. Under the collaboration, Curigin will use the capabilities of Charles River in contract development and manufacturing organisation (CDMO)
Drug DiscoveryResearch & Development June 12, 2023 EdgeCap Partners buys majority stake in Comac Medical By PBR Staff Writer Comac founder and CEO Dr Milen Vrabevski and its other shareholders will retain a significant minority stake. The companies have not disclosed the financial terms of the deal.
Women's Health June 9, 2023 Cosette acquires worldwide rights to Endoceutics’ Intraros prescription drug By PBR Staff Writer The transaction includes 108 issued and pending patents globally with the latest expiring this year including three Orange Book listed patents. The acquisition will expedite Cosette’s women’s health
Drug Manufacturing June 8, 2023 Samsung Biologics, Pfizer partner for biosimilars portfolio manufacturing By PBR Staff Writer Initially, the companies signed a manufacturing agreement in March last year for a Pfizer product. As per the new agreement terms, Samsung Biologics will provide Pfizer with more
Oncology June 7, 2023 Janssen seeks US FDA approval of new indication for Carvykti By PBR Staff Writer Carvykti is intended to treat adults with relapsed or refractory multiple myeloma who have previously received a minimum of one line of therapy including a proteasome inhibitor, an
Inflammation June 6, 2023 Rani, Celltrion expand partnership for development of adalimumab biosimilar By PBR Staff Writer Under a new license and supply agreement, Celltrion will supply adalimumab biosimilar drug substance CT-P17 that is required for RT-105. Rani has an exclusive license to use the
Gastric Cancer June 5, 2023 NMPA grants BTD to Innovent’s olverembatinib to treat SDH-deficient GIST By PBR Staff Writer The designation was granted based on the results from an ongoing Phase Ib/II study of olverembatinib carried out in China. The study demonstrated a clinical benefit rate of
Osteoarthritis June 2, 2023 Levolta partners with Tabuk for OA therapy commercialisation in MEA region By PBR Staff Writer Tabuk is a fully owned subsidiary of Astra Industrial Group. Under the agreement, Tabuk will hold the marketing authorisation and will be responsible for registering, importing, and commercialising